Insert Therapeutics Treats Patient with Nano-Engineered Anti-Cancer Therapeutic
Complete the form below to unlock access to ALL audio articles.
Arrowhead Research Corporation has announced that its majority-owned subsidiary, Insert Therapeutics has treated its first patient in a Phase I study of IT-101, Insert's lead anti-cancer compound.
"The initiation of the clinical development phase for IT-101 is an important milestone for Insert Therapeutics," said Dr. Thomas Schluep, Chief Scientific Officer at Insert Therapeutics.
"It demonstrates our commitment to bringing innovative therapies to the clinic that address significant, unmet patient needs."
The study is an open-label, dose-escalation Phase I study in patients with inoperable or metastatic solid tumors and has been designed to evaluate the safety, tolerability and pharmacokinetics of IT-101.
Insert expects that between 24 and 48 patients will be enrolled in the study during its course. The study is currently being conducted at The City of Hope Cancer Center (COH) in Duarte, CA, where Yun Yen, MD., Ph.D. will lead the study.
"We congratulate the team at Insert on this latest success," said R. Bruce Stewart, Arrowhead's Chairman.
"While the Phase I study is underway, Insert will continue preparations for IT-101's further clinical trials and the development of its next therapeutic candidates."
